Template:Gatifloxacin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Gatifloxacin |{{fontcolor|#6C7B8B|Gatifloxacin}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Gatifloxacin |{{fontcolor|#6C7B8B|Gatifloxacin}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |GATIFLOXACIN<sup>®</sup>,ZYMAXID<sup>®</sup>,ZYMAR<sup>®</sup><br>FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |GATIFLOXACIN<sup>®</sup>,ZYMAXID<sup>®</sup>,ZYMAR<sup>®</sup><br>FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin description|Description]] | ||
| Line 14: | Line 14: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin warnings|Warnings | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin warnings and precautions|Warnings and Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin adverse reactions|Adverse Reactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin adverse reactions|Adverse Reactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin clinical studies|Clinical Studies]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin clinical studies|Clinical Studies]] | ||
| Line 27: | Line 23: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin how supplied|How Supplied]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin labels and packages|Labels and Packages]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Gatifloxacin labels and packages|Labels and Packages]] | ||
|- | |- | ||
|} | |} | ||
Latest revision as of 21:45, 8 January 2014
| Gatifloxacin |
|---|
| GATIFLOXACIN®,ZYMAXID®,ZYMAR® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Clinical Studies |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |